Objective: To explore water soluble metabolite features of brain tumor specimens with HRMAS-1HMRS and its potential clinical value. Methods: There were thirty cases of pathologically proven brain tumor, including 6 I-II grade astrocy- tomas, 7 III grade anaplastic astrocytomas, 10 IV grade glioblastomas and 7 meningiomas. Used Varian Company 600 MHz spectrometer with the Nano-probe for acquisition HRMAS-1HMRS, which was postprocessed with jMRUI 3.2 version software. These metabolic probability and their ratios to Cr were summed. Results: (1) HRMAS-1HMRS could resolve NAA, PCr/Cr, GPC + PCho + Cho, Glu/Gln, Gly, Tau, Ala, Lac, mI and so on. All samples showed Lac, 6 samples showed unknown single peak at 3.72 ppm or 3.90 ppm. (2) The mean Cho/Cr of 6 I-II grade astrocytomas was 2.42 ± 1.01 (P = 0.003, compared with glioblastoma). The mean Cho/Cr of 7 anaplastic astrocytomas was 3.48 ± 0.59 (P = 0.01, compared with glioblastoma). The Cho/Cr of 10 glioblastomas broadly ranged from 0.9 to 11.3 (mean 5.40 ± 1.23). From I-II grade astrocytoma to glioblastoma, Ala/Cr, Tau/Cr and Gly/Cr trends were increased; the mean Ala/Cr of glioma was 0.31 ± 0.13. (3) Meningiomas showed higher Ala and Cho. Their Cr was lower than that of gliomas. 4/7 cases had no NAA, 3/7 patients had lower NAA. Mean Cho/Cr was 3.56 ± 1.01, Ala/Cr was 0.53 ± 0.28 (P = 0.006, compared with glioma). Conclusion: HRMAS-1HMRS can show further details in vivo MRS, resolve in vivo spectroscopic metabolite of Cho compound and differentiate the extent of benign and ma- lignant glioma. With the increase in the malignant degree of gliomas, Cho, mI, Ala, Tau and Gly will increase. HRMAS-1HMRS is the only method of isotropic spectroscopy for pathological specimens.
展开▼
